Research

Hormonal

Short-acting GLP-1 receptor agonists (exenatide twice daily, lixisenatide) produce greater reductions in postprandial glucose than long-acting agents (liraglutide, dulaglutide, exenatide once weekly) due to delayed gastric emptying, whereas long-acting agents provide superior fasting glucose control.

If you struggle with blood sugar spikes after meals, short-acting GLP-1 drugs (taken twice daily or before meals) may work better for you. If your main issue is high fasting blood sugar in the morning, long-acting GLP-1 drugs (taken once daily or weekly) are likely more effective. Discuss these options with your doctor to match the drug's mechanism to your specific glucose pattern.

GoodQualifiesHIGH confidence
As the short-acting GLP-1RAs delay gastric emptying, they have greater effects on postprandial glucose levels than the longer-acting agents, whereas the longer-acting compounds reduced plasma glucose throughout the 24-h period studied.
Sten Madsbad · Diabetes Obesity and Metabolism · 2015

Why this rating

Based on a review of nine phase III head-to-head trials and one phase II study.

Source

Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists

Sten Madsbad · Diabetes Obesity and Metabolism · 2015

DOI 10.1111/dom.12596

narrative_reviewCited 292×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →